425: Scilex Holding Subsidiary Semnur Pharmaceuticals Announces Filing of Registration Statement for Business Combination with Denali Capital Acquisition Corp.

Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company, announced the filing of a registration statement on Form S-4 by Denali Capital Acquisition Corp. related to their previously announced business combination.

Summary

• Scilex Holding Company's subsidiary, Semnur Pharmaceuticals, is proceeding with its business combination with Denali Capital Acquisition Corp.
• Denali has filed a Registration Statement on Form S-4 with the SEC, which includes a preliminary proxy statement and prospectus.
• The business combination is expected to close by the first quarter of 2025.
• Scilex declared a stock dividend of 5,000,000 shares of Series 1 Mandatory Exchangeable Preferred Stock to Scilex stockholders and certain other securityholders as of the record date.
• This preferred stock will be exchangeable for up to 10% of Scilex's ownership interest in Semnur following the closing of the Business Combination and are expected to be freely tradable upon such exchange.
• The record date for the dividend of Scilex preferred stock is November 7, 2024.
• The pre-transaction equity value of Semnur is estimated at $2.5 billion.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in the business combination and the potential for future growth in the non-opioid pain management market. However, there are inherent risks associated with forward-looking statements and the completion of the transaction.

Positives

• The filing of the Registration Statement is a step forward in the business combination between Semnur and Denali.
• The stock dividend provides value to Scilex stockholders.
• The combined company aims to focus on non-opioid pain management products.

Risks

• The business combination may not be completed.
• The anticipated benefits of the business combination may not be realized.
• The combined company may face challenges in growing and managing growth profitably.
• The combined company may not be able to obtain or maintain the listing of its securities on Nasdaq.
• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The combined company will focus on non-opioid pain management products and aims to improve patient outcomes.

Industry Context

The announcement reflects the ongoing trend of SPAC mergers in the pharmaceutical industry, particularly for companies focused on innovative pain management solutions.

Stakeholder Impact

• Scilex stockholders will receive a stock dividend.
• Denali shareholders will vote on the business combination.
• The combined company will aim to provide non-opioid pain management solutions to patients.

Next Steps

• Denali will mail a definitive proxy statement/final prospectus to its shareholders.
• Denali's shareholders will hold an extraordinary general meeting to approve the Business Combination.
• The SEC will need to declare the Registration Statement effective.
• The business combination is expected to close in the first quarter of 2025.

Key Dates